Determinants of high platelet reactivity in patients with acute coronary syndromes treated with ticagrelor

[1]  E. Navarese,et al.  Metabolism of ticagrelor in patients with acute coronary syndromes , 2018, Scientific Reports.

[2]  J. McEvoy,et al.  Fentanyl Delays the Platelet Inhibition Effects of Oral Ticagrelor: Full Report of the PACIFY Randomized Clinical Trial , 2018, Thrombosis and Haemostasis.

[3]  J. Wasfy,et al.  In‐hospital outcomes in invasively managed acute myocardial infarction patients who receive morphine , 2018, Journal of interventional cardiology.

[4]  Marco Valgimigli,et al.  2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). , 2018, European heart journal.

[5]  W. Herzog,et al.  Effect of Intravenous Fentanyl on Ticagrelor Absorption and Platelet Inhibition Among Patients Undergoing Percutaneous Coronary Intervention: The PACIFY Randomized Clinical Trial (Platelet Aggregation With Ticagrelor Inhibition and Fentanyl). , 2017, Circulation.

[6]  I. Barbash,et al.  Effect of Chewing vs Swallowing Ticagrelor on Platelet Inhibition in Patients With ST-Segment Elevation Myocardial Infarction: A Randomized Clinical Trial , 2017, JAMA cardiology.

[7]  M. Marszałł,et al.  Comparison of bioavailability and antiplatelet action of ticagrelor in patients with ST-elevation myocardial infarction and non-ST-elevation myocardial infarction: A prospective, observational, single-centre study , 2017, PloS one.

[8]  P. Adamski,et al.  Polish trials influencing 2017 European Society of Cardiology guidelines on acute myocardial infarction in patients presenting with ST-segment elevation , 2017, Postepy w kardiologii interwencyjnej = Advances in interventional cardiology.

[9]  M. Marszałł,et al.  Comparison of Ticagrelor Pharmacokinetics and Pharmacodynamics in STEMI and NSTEMI Patients (PINPOINT): protocol for a prospective, observational, single-centre study , 2017, BMJ Open.

[10]  M. Marszałł,et al.  Crushed sublingual versus oral ticagrelor administration strategies in patients with unstable angina , 2017, Thrombosis and Haemostasis.

[11]  I. Barbash,et al.  Chewing versus Swallowing Ticagrelor to Accelerate Platelet Inhibition in Acute Coronary Syndrome - the CHEERS study , 2017, Thrombosis and Haemostasis.

[12]  J. Kubica,et al.  New directions for pharmacotherapy in the treatment of acute coronary syndrome , 2016, Expert opinion on pharmacotherapy.

[13]  M. Marszałł,et al.  Which platelet function test best reflects the in vivo plasma concentrations of ticagrelor and its active metabolite? , 2016, Thrombosis and Haemostasis.

[14]  M. Marszałł,et al.  Impact of ticagrelor administration strategy on its pharmacokinetics and pharmacodynamics in patients with unstable angina pectoris: a protocol of a randomized study , 2016 .

[15]  P. Gurbel,et al.  Impact of morphine on antiplatelet effects of oral P2Y12 receptor inhibitors. , 2016, International journal of cardiology.

[16]  M. Marszałł,et al.  Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial , 2015, European heart journal.

[17]  Jeroen J. Bax,et al.  2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). , 2011, European heart journal.

[18]  Baris Gencer,et al.  ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation , 2011 .

[19]  I. Xanthopoulou,et al.  Crushed Versus Integral Tablets of Ticagrelor in ST-Segment Elevation Myocardial Infarction Patients: A Randomized Pharmacokinetic/Pharmacodynamic Study , 2016, Clinical Pharmacokinetics.

[20]  D. Angiolillo,et al.  Impact of Escalating Loading Dose Regimens of Ticagrelor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Results of a Prospective Randomized Pharmacokinetic and Pharmacodynamic Investigation. , 2015, JACC. Cardiovascular interventions.

[21]  M. Price,et al.  Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. , 2015, European heart journal.

[22]  R. Teng.  Ticagrelor: Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Profile: An Update , 2015, Clinical Pharmacokinetics.

[23]  R. Abbate,et al.  Ticagrelor crushed tablets administration in STEMI patients: the MOJITO study. , 2015, Journal of the American College of Cardiology.

[24]  I. Xanthopoulou,et al.  Morphine Is Associated With a Delayed Activity of Oral Antiplatelet Agents in Patients With ST-Elevation Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention , 2014, Circulation. Cardiovascular interventions.

[25]  A. Jaffe,et al.  Platelet function testing in acute cardiac care – is there a role for prediction or prevention of stent thrombosis and bleeding? , 2014, Thrombosis and Haemostasis.

[26]  A. Andruszkiewicz,et al.  Time-related changes in determinants of antiplatelet effect of clopidogrel in patients after myocardial infarction. , 2014, European journal of pharmacology.

[27]  E. Vicaut,et al.  Prehospital ticagrelor in ST-segment elevation myocardial infarction. , 2014, The New England journal of medicine.

[28]  E. Navarese,et al.  Overview of pleiotropic effects of platelet P2Y12 receptor inhibitors , 2014, Thrombosis and Haemostasis.

[29]  Deepak L. Bhatt,et al.  Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. , 2013, Journal of the American College of Cardiology.

[30]  R. Abbate,et al.  Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. , 2013, Journal of the American College of Cardiology.

[31]  Erling Falk,et al.  Update on acute coronary syndromes: the pathologists' view. , 2013, European heart journal.

[32]  Fred S Apple,et al.  Third universal definition of myocardial infarction , 2012 .

[33]  D. Atar,et al.  ESC Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting With ST-Segment Elevation , 2013 .

[34]  M. Price,et al.  Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data. , 2011, Journal of the American College of Cardiology.

[35]  C. Cannon,et al.  Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. , 2007, Journal of the American College of Cardiology.

[36]  C. Macaya,et al.  Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. , 2007, Journal of the American College of Cardiology.

[37]  L. Hillis,et al.  Antiplatelet therapy for ischemic heart disease. , 2004, The New England journal of medicine.

[38]  R. Wilcox,et al.  Open Multicentre Study of the P 2T Receptor Antagonist AR-C69931MX Assessing Safety, Tolerability and Activity in Patients with Acute Coronary Syndromes , 2001, Thrombosis and Haemostasis.

[39]  S. Zeger,et al.  Longitudinal data analysis using generalized linear models , 1986 .